

1/19

6458369





FIG. 1


22



APPROVED	FIG.
BY	SUBCLASS
DRAFTSMAN	424 277.1

3/19

Figure 3



4/19




FIG. 4

5/19





FIG. 5

6/19

Figure 6



7/19




FIG. 7

8/19




FIG. 8

9/19




FIG. 9

10/19




FIG. 10

11/19




FIG. 11A

12/19




FIG. 11B

APPROVED	C.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN	424	27.1

13/19

ADJUVANT TREATMENTS IN STAGE 2 MELANOMA




FIG. 12

14/19

**T CELL STIMULATION BY PEPTIDES
FROM DNP-MODIFIED MELANOMA CELLS**




FIG. 13

APPENDIX	FIG. 1
TY	780
DRAFTSMAN	424
	277.1
SUBCLASS	

15/19



FIG. 14A




FIG. 14B

664090-03840660

16/19




FIG. 15A




FIG. 15B

APPROVED	D.G. FIG. . .	
BY	CLASS	SUBCLASS
DRAFTSMAN	424 27.1	

17/19

Patient

C 1 2 3 4 5 6 7



IL10

C cDNA Control

FIG. 16

18/19




FIG. 17



FIG. 18A




FIG. 18B